Helyx Industries S.p.A.

01/18/2022 | Press release | Archived content

Hyris bCUBE SARS-CoV-2 rapid molecular saliva testing: a POCT innovation on its way

Hyris bCUBE SARS-CoV-2 rapid molecular saliva testing: a POCT innovation on its way

The reliable identification of individuals with SARS-CoV-2 infection is the cornerstone for containing viral spread. Rapid molecular point-of-care testing (POCT) of saliva might reduce analysis time, thus increasing the efficacy of contact tracing. In this study, a new POCT RT-PCR assay for the detection of SARS-CoV-2 RNA in saliva was evaluated and compared with an already validated CE-IVD method.
De Gruyter | 2022
Helyx Industries S.p.A. published this content on January 18, 2022, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on December 17, 2025 at 14:34 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]